Roger Alvarez
Pulmonary Disease · Weston, FLNPI 1457593832
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,623 of the $81,662 with a category attached, or 69.3%. United Therapeutics Corporation accounts for 84.9% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $29,682, 5.3 times the $5,588 reported in 2019. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $540.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$69K
- Penumbra, Inc.$10K
- Actelion Pharmaceuticals US, Inc.$887
- Inari Medical, Inc.$384
- Boehringer Ingelheim$244
- Merck$145
- plus $658 from 9 others
Across 40 payments — averaging $2477.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$78K
- Inari Medical, Inc.$21K
What the payments were for
- Consulting fees$9,79312%
- Speaking & faculty fees$56,62369%
- Travel & lodging$8,63711%
- Food & beverage$6,4928%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 100 | $69,370 |
| Penumbra, Inc. | 11 | $9,973 |
| Actelion Pharmaceuticals US, Inc. | 17 | $887 |
| Inari Medical, Inc. | 4 | $384 |
| Boehringer Ingelheim | 5 | $244 |
| Merck | 1 | $145 |
| Atricure, Inc. | 1 | $110 |
| Boston Scientific | 1 | $109 |
| Argon Medical Devices, Inc. | 1 | $101 |
| Angiodynamics, Inc. | 1 | $96 |
| Bayer | 4 | $88 |
| Intuitive Surgical | 1 | $65 |
| GSK | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Genentech, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$18,356
- Indigo System$9,855
- NONE$4,858
- UPTRAVI$362
- FLOWTRIEVER CATHETER, S$251
- OPSUMIT$250
- ORENITRAM$124
- REMODULIN$124
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2)$110
- GENERAL VASCULAR ACCESS$109
- Clot Management$101
How this compares
$81,662 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 120 | $1,628,887 |
| OpsumitMacitentan | 108 | $1,381,585 |
| OfevNintedanib Esylate | 47 | $671,769 |
| Orenitram ErTreprostinil Diolamine | 67 | $586,110 |
| UptraviSelexipag | 16 | $353,914 |
| Tyvaso DpiTreprostinil | 11 | $247,511 |
| Ambrisentan | 41 | $188,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $102,910 |
| Pirfenidone | 19 | $47,607 |
| JardianceEmpagliflozin | 19 | $27,854 |
| Tadalafil | 51 | $23,970 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $9,273 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $9,119 |
| Arnuity ElliptaFluticasone Furoate | 28 | $8,368 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $887 | $1,735,500124 claims |
| BayerAdempas | $88 | $1,628,887120 claims |
| Boehringer IngelheimOfev, Jardiance, Stiolto Respimat | $244 | $708,74286 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta | $39 | $130,978199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Weston
- Franck RahaghiWeston$1.2M
- Anas HadehWeston$800K
- David ZismanWeston$112K
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.